Log In
Print
BCIQ
Print
Print this Print this
 

bevacizumab (ABP 215)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar to bevacizumab
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat metastatic non-small cell lung cancer (NSCLC)
Regulatory Designation

Partner

Allergan plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today